IMPOWER132

NCT02657434 📎

Regimen

Experimental
atezolizumab + carbo/cis + pemetrexed
Control
carbo/cis + pemetrexed

Population

1L non-sq NSCLC EGFR/ALK-WT

Key finding

PFS HR 0.60 (0.49-0.72); OS HR 0.86 (0.71-1.06) NS; positive PFS, negative OS

Source: PMID 33462883

Timeline

  • Enrollment start: 2016-04-30 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source